Answers are grounded in this paper and cite their sources.
The Abbreviated New Drug Application (ANDA) process is pivotal in facilitating the availability of generic drugs, offering cost-effective alternatives to branded medications while ensuring patient safety and therapeutic efficacy. This review delves into the critical considerations involved in ANDA evaluation, focusing on the regulatory balance required to maintain drug quality and accessibility. Key elements such as bioequivalence, therapeutic equivalence, and compliance with Good Manufacturing Practices (GMP) are scrutinized to highlight their roles in safeguarding patient outcomes. The review also addresses the challenges posed by evolving drug formulations, manufacturing technologies, and the increasing complexity of global supply chains. Additionally, it discusses the regulatory frameworks that guide ANDA approvals, emphasizing the importance of rigorous post-marketing surveillance to detect and mitigate potential safety issues. Through an analysis of recent case studies and regulatory updates, the review identifies best practices and suggests potential areas for improvement in the ANDA process. By ensuring that generic drugs remain safe, effective, and accessible, the ANDA framework continues to play a vital role in public health.
No takes yet. Share an insight, caveat, or question.
Samyukta et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: